信达生物:2025 中期报告

香港交易所
Sep 29

牛牛AI助手已提取核心信息信达生物2025年上半年收入达59.53亿元人民币,同比增长50.6%,主要受益于肿瘤产品的持续强劲表现、综合产品线的贡献增加和授权费收入增加。期内实现转亏为盈,净利润8.34亿元,Non-IFRS利润12.13亿元,Non-IFRS EBITDA达14.13亿元,反映出经营效率的持续提升。公司产品组合已扩展至16款获批产品,报告期内成功商业化上市五款新药,包括肿瘤领域的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10